Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

Total
0
Shares
Related Posts
Read More

Cinedigm Rebrands To Cineverse

New Brand Marks the Transformation to a Pure-play Streaming Entertainment Content and Technology Company Reimagining the Entertainment ExperienceLOS ANGELES, May 22, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ:CIDM)

CIDM